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910Background: Proinflammatory (M1) macrophages and anti-inflammatory (M2) mac-
rophages have been identified in atherosclerotic plaques. While these macrophages
have been speculated to be related to plaque vulnerability, there are limited studies
investigating this relationship. Therefore, we examined the association between
macrophage phenotype (M1 versus M2) and plaque vulnerability and clinical
events. Methods: Patients undergoing carotid endarterectomy received an ultra-
sound of the carotid artery before surgery. Plaques were processed for analysis by
immunohistochemistry, Western blotting, and real-time polymerase chain reaction
studies. Medical history and clinical data were obtained from medical records.
Results: Patients were divided into 2 groups: those suffering from acute ischemic
attack (symptomatic, n5 31) and those that did not present with symptoms (asymp-
tomatic, n5 34). Ultrasound analysis revealed that plaque vulnerability was greater
in the symptomatic group (P5 .033; Chi-square test). Immunohistochemistry
revealed that plaques from the symptomatic group had a greater concentration of
M1 macrophages (CD68-, CD11c-positive) while plaques from the asymptomatic
group had more M2 macrophages (CD163-positive). This observation was con-
firmed byWestern blotting. Characterization by real-time polymerase chain reaction
studies revealed that plaques from the symptomatic group had increased expression
of the M1markers CD68 and CD11c, as well as monocyte chemoattractive protein-1,
interleukin-6, and matrix metalloproteinase-9. In addition, more M1 macrophages
expressed in unstable plaques were defined by ultrasound analysis, while more
M2 macrophages were expressed in stable plaques. Conclusions: Our data show
that M1 macrophage content of atherosclerotic plaques is associated with clinical
incidence of ischemic stroke and increased inflammation or fibrinolysis. We
also show the benefits of using ultrasound to evaluate vulnerability in the
plaques. Key Words: Atherosclerosis—carotid artery disease—inflammation—
macrophage—stroke.
 2013 by National Stroke Associationof Internal Medicine II, Hokkaido Univer-
Medicine, Sapporo; †Department of Neu-
chool of Medicine and Pharmaceutical
niversity of Toyama, Toyama; ‡Sapporo
ospital, Sapporo; xNakamura Memorial
kSapporo City General Hospital, Sapporo,
2, 2012; revision received October 28, 2012;
012.
Supported by grants from the Japanese Ministry of Education,
Culture, Sports, Science, and Technology Foundation (H.M.) and
Suzuken Memorial Foundation (H.M.).
Address correspondence to Hideaki Miyoshi, MD, PhD, Depart-
ment of Internal Medicine II, Hokkaido University Graduate School
of Medicine, North 15, West 7, Kita-ku, Sapporo, Hokkaido 060-
8638, Japan. E-mail: hmiyoshi@med.hokudai.ac.jp.
1052-3057/$ - see front matter
 2013 by National Stroke Association
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2012.11.020
Journal of Stroke and Cerebrovascular Diseases, Vol. 22, No. 7 (October), 2013: pp 910-918
MACROPHAGE PHENOTYPE INFLUENCES PLAQUE STABILITY 911Atherosclerotic disease in the carotid artery is one im-
portant cause of ischemic stroke. Ischemic stroke is esti-
mated to be responsible for .10% of all deaths and is the
second cause of mortality worldwide.1 Atherosclerosis is
a progressive and chronic inflammatory disease in which
lipids, immune cells, vascular smoothmuscle cells, and ex-
tracellular matrix accumulate in the subendothelial space
to form the growing atherosclerotic lesion.2 The inflamma-
tory reaction taking place in plaques relies on highly com-
plex processes that are still not completely understood.
However, it is known that recruited leukocytes are key fa-
cilitators of these events. In mononuclear phagocytes, the
so-called M1 and M2 activation pathways are thought to
represent the embodiment of the control switches in innate
immune response, creating abalancebetweenaproinflam-
matory environment and an anti-inflammatory environ-
ment.3 The M1 pathway is characterized by the synthesis
of proinflammatory cytokines that are potentially harmful
in the context of atheroma, while anti-inflammatory/
reparative M2 macrophages are derived from monocytes
activated along the alternative pathway.4,5
It is well known that the risk of cardiovascular events is
related to the composition and stability of the plaque
rather than to the degree of arterial stenosis, and recent
studies suggest that inflammation is a critical determinant
of plaque stability. Vulnerable plaque imaging techniques
currently allow the analysis of plaque morphology and
characteristics.6-8
In this study, we aim to investigate the relationship be-
tween macrophage polarity (M1 versus M2) and the vul-
nerability of human atherosclerotic plaques. Patients
undergoing carotid endarterectomy (CEA) were divided
into 2 groups: those suffering from cerebral infarction
(symptomatic group) and those that did not present
with symptoms (asymptomatic group). Plaques obtained
from both populations were studied to determine the na-
ture of the macrophages associated with the plaque and
their association with atherosclerotic factors.Methods
Patients
Between November 2008 and April 2011, 65 patients
underwent CEA at Sapporo Asabu Neurosurgical Hospi-
tal, Nakamura Memorial Hospital, Sapporo City General
Hospital, or Hokkaido University Hospital. Written in-
formed consent from each patient was obtained before en-
rollment in the study, which was performed according to
Good Clinical Practice and Helsinki Declaration princi-
ples. The ethics committees of each hospital and Hok-
kaido University approved the studies.Inclusion Criteria
Patients who had high-grade (.70%) stenosis and were
asymptomatic or intermediate stenosis (.50%) for symp-tomatic patients in the internal carotid artery according to
the North American Symptomatic Carotid Endarterec-
tomy Trial (NASCET)9 and Japanese Guidelines for the
Management of Stroke criteria1 confirmed by carotid
B-mode ultrasound were collected. The clinical indication
for CEA was met after examination by the neurologist
based on the guidelines.Patient Characteristics, History, and Medication
Medical history was recorded from all patients, and the
presence of vascular risk factors, features ofmetabolic syn-
drome, and medications were noted. Clinical history was
assessed for diabetes mellitus, smoking, hypertension,
dyslipidemia, previous acute cerebrovascular or myocar-
dial infarction, andperipheral vascular disease.Hyperten-
sionwas diagnosed according to the Seventh Report of the
Joint National Committee on Prevention, Detection, Eval-
uation, and Treatment ofHigh Blood Pressure (JNC-7) and
the Japanese Society of Hypertension Guidelines for the
Management of Hypertension (JSH 2009) criteria (blood
pressure $140/90 mm Hg or $130/80 mm Hg [with dia-
betes mellitus] or current antihypertensive treatment).10
Diabetes was diagnosed in patients with dietary treat-
ment, those taking antidiabetic medications, or those
with current fasting plasma glucose levels .7.0 mmol/L.
Diagnosis of dyslipidemia was made according to the
Japan Atherosclerosis Society Guidelines for Prevention
of Atherosclerotic Cardiovascular Diseases 2007 when
$1 of the following lipid abnormalities was present:
low-density lipoprotein cholesterol (LDL-C) $3.6 mmol/L
(LDL-C was determined using the Friedewald equation),
high-density lipoprotein cholesterol,1.0 mmol/L, triglyc-
erides$1.7mmol/L, or when a patient was taking a lipid-
lowering drug. Fasting blood samples were taken before
CEA for analysis (Table 1).Definition of Symptomatic Carotid Disease
Patients were categorized by their physician as either
symptomatic or asymptomatic based on an evaluation of
their history and a clinical examination. Patients who
had acute onset focal neurologic symptoms were consid-
ered symptomatic, and the median number of days be-
tween the acute clinical events and the CEA was 21.5
days (range 8-40 days) in the symptomatic group. Patients
who experienced acute clinical events more than 6 months
earlier were considered asymptomatic.Carotid B-mode Ultrasound
The carotid arteries were carefully examined before
surgery with commercially available equipment (GE
Healthcare LOGIQ9 with 9-MHz linear array transducer;
Waukesha, WI). Echo imaging and the evaluation of the
degree of stenosis was performed by a well-trained oper-
ator who was unaware of the clinical profile of the
Table 1. Patient clinical characteristics and current medications at time of enrollment into the study
Characteristics Asymptomatic (n 5 34) Symptomatic (n 5 31) P value
Age, y* 69 (48-80) 71 (50-82) .41
Males, n (%) 27 (79.4) 25 (83.3) .94
Body mass index, kg/m2* 23.4 (17.1-31.3) 23.3 (20.6-27.7) .95
Risk factors, n (%)
Hypertension 25 (73.5) 26 (83.9) .44
Coronary heart disease 13 (38.2) 9 (29.0) .49
Diabetes mellitus 19 (55.9) 14 (45.2) .33
Dyslipidemia 23 (67.8) 21 (71.0) .73
Current smoking 4 (11.7) 5 (16.2) .64
Former smoking 9 (26.4) 7 (22.6) .71
Cerebrovascular disease treated 13 (38.2) 10 (33.2) .74
Drugs, n (%)
Antiplatelet agents 25 (73.5) 21 (67.8) .73
Anticoagulation 4 (11.7) 5 (16.1) .64
ACE inhibitors 2 (5.9) 4 (12.9) .56
ARBs 15 (44.1) 14 (45.2) .84
Beta-blockers 6 (17.6) 7 (22.9) .68
Calcium channel blockers 17 (50.0) 14 (45.2) .75
Diuretics 6 (17.6) 4 (12.9) .64
OADs 13 (38.2) 10 (32.3) .74
Insulin 4 (11.8) 2 (6.5) .56
Statin 21 (61.8) 17 (54.8) .77
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; OAD, antihyperglycemic drug.
P values determined by the unpaired Student t or Mann–Whitney U test where applicable.
*Median (range).
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sicians to determine the condition of the arterial surface.
Consistent with previous research and to ensure unifor-
mity and an unbiased approach in the analysis, these in-
dividuals were also unaware of the clinical profile of the
patients.11 Plaque morphology in terms of echogenicity
was used to assess plaque stability. Plaques with a smooth
wall surface and no echolucent material were considered
stable; those with an irregular surface, ulceration, wall
flap,12,13 or with predominantly echolucent material
were classified as unstable.14,15Human Atherosclerosis
CEAwas performed on patients under sedation and an-
esthesia. Obtained specimens were immediately rinsed in
saline and cut into pieces including the most prominent
region of the plaque. One section was collected into RNA-
later solution (Qiagen, Valencia, CA) for subsequent RNA
extraction, the second was pulverized for protein analy-
sis, the third was fixed in formaldehyde for morphologic
analysis, and the other sections were stored at –80C.Immunohistochemistry
The specimenswere embedded in paraffin. After depar-
affination, to remove endogenous peroxidase, the sections
were embedded in hydrogen peroxidase and methanol.Sections were then incubated with mouse monoclonal
antihuman CD68 (1:100; Dako Cytomation, Glostrup,
Denmark), mouse monoclonal anti-CD11c (1:100; Dako),
goat polyclonal antihuman Mannose Receptor (MR)
(1:100; R&D Systems, Minneapolis, MN), mouse monoclo-
nal antihuman CD163 (1:100; Leica Biosystems, Newcastle
Upon Tyne, United Kingdom), mouse monoclonal antihu-
man matrix metalloproteinase-2 (MMP-2; 1:100; Abcam,
Cambridge, MA), and goat polyclonal antihuman MMP-9
(1:100; R&D Systems) overnight at 4C. Controls without
primary antibody were run for each protocol, resulting in
consistentlynegativeobservations.Sectionswere incubated
withbiotin-conjugatedantimouseorantigoat immunoglob-
ulin G (IgG), treatedwith peroxidase-conjugated streptavi-
din, and stainedwith a 3, 30-diaminobenzidine substrate kit
(Nichirei Bioscience, Tokyo, Japan).RNA Extraction and Analysis
RNAlater-stored plaques (n 5 65) were removed from
RNAlater and milled with a rotor-stator homogenizer. To-
tal cellular RNAwas extractedwith a TRI Regent (Qiagen)
and purified with the RNeasy Total RNA Isolation Kit
(Qiagen) according to the manufacturer’s recommenda-
tions. cDNA was synthesized from 0.5 mg of total RNA
(high capacity RNA-to-cDNA kit; Applied Biosystems,
Warrington, United Kingdom). A real-time polymerase
chain reaction (PCR) study was performed in triplicate
Table 2. Patient blood chemistry parameters at time of study enrollment*
Parameter Asymptomatic (n 5 34) Symptomatic (n 5 31) P value
Platelets, 3109/L 195 6 46 203 6 50 .61
Hemoglobin, g/L 125 6 18 133 6 12 .18
WBC, 3109/L 6.2 6 1.6 6.0 6 1.1 .62
Creatinine, mmol/L 80.9 6 47.5 84.6 6 20.7 .75
Uric acid, mmol/L 0.80 6 .40 0.80 6 .39 .88
Total cholesterol, mmol/L 4.3 6 1.7 4.1 6 .6 .51
HDL cholesterol, mmol/L 1.1 6 .6 1.0 6 .5 .52
LDL cholesterol, mmol/L 2.3 6 1.5 2.1 6 1.0 .51
Serum triglycerides, mmol/L 3.1 6 2.1 3.7 6 1.7 .31
Fasting plasma glucose, mmol/L 7.6 6 2.8 7.2 6 3.2 .68
Hemoglobin A1c, % 6.1 6 1.0 5.7 6 .8 .33
CRP, 3104 mg/Ly 1.7 (0.0-4.3) 1.5 (0.0-6.8) .78
Abbreviations: CRP, C-reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; WBC, white blood cell count.
P values determined by the unpaired Student t or Mann–Whitney U test.
*Values are reported as the mean 6 standard deviation.
yValue reported as median (range).
Table 3. Ultrasound determination of carotid stenosis and













Mixed echoic 5 3




Wall flap 0 1
Total occlusion 1 3
Vulnerability, n
Stable 21 11
Unstable 13 20 .033y
*Mann–Whitney U test. Values are reported as mean 6 standard
deviation.
yP , .05 using the Chi-square test.
MACROPHAGE PHENOTYPE INFLUENCES PLAQUE STABILITY 913on a 7500 Fast Real Time PCR system using SYBR Green
PCR Master Mix (Applied Biosystems). Relative gene ex-
pression was determined by the comparative critical
threshold method, normalizing expression to 18S.
Protein Extraction and Immunoblot Analysis
Samples (n 5 65) were pulverized with a homogenizer
in a Tris-ethylenediaminetetra-acetic acid (EDTA) buffer
containing 10 mM Tris/hydrochloric acid (pH 7.4) and
1 mM EDTA. Equal amounts (30 mg) of proteins were sep-
arated on 10% sodium dodecyl sulfate–polyacrylamide
gel and transferred to a nitrocellulose membrane. The pri-
mary antibodies used were CD68 (1:1000), CD11c (1:100),
CD168 (1:500), and MR (1:100). Actin was used as a load-
ing control. Secondary antibodies were antimouse IgG
(CD68, CD11c, and CD168) or antigoat IgG (MR). To en-
sure equal loading, membranes were stripped and re-
probed with the use of goat antihuman actin AB (1:2000;
Santa Cruz Biotechnology, Santa Cruz, CA). Analysis
was performed using Amersham ECL Advance Western
blotting detection kit (GE Healthcare, Little Chalfont,
United Kingdom), and images were obtained using
a CCD-camera system LAS-4000 UV mini (Fujifilm,
Tokyo, Japan).
Statistical Analysis
Data were summarized using mean and standard devi-
ation or median, minimum, maximum as appropriate for
continuous variables and counts as well as percentages
for categorical variables. Data distribution was analyzed
using the Kolmogorov–Smirnov test. According to these
results, appropriate parametric or nonparametric tests
were used in further analyses. Unpaired Student t or
Mann–Whitney U tests were performed to assess differ-
ences among quantitative variables. The Chi-square testwas applied to analyze differences in qualitative and cat-
egorical variables. Data were analyzed using JMP for
Windows software (version 9.0.2; SAS Institute, Cary,
NC) and P ,.05 was considered statistically significant.Results
Sixty-five patients (52 males and 13 females; mean age
68.9 years old) were stratified into 2 groups: the asymp-
tomatic group (n 5 34) and the symptomatic group
(n 5 31). The patients’ clinical characteristics and
Figure 1. Symptomatic plaques are characterized by an increased concentration of M1 macrophages and greater expression of fibrinolytic enzymes. Specimens
were obtained from patients undergoing carotid endarterectomy. Patients were categorized as either symptomatic or asymptomatic based on an evaluation of their
patient history and a clinical examination. Representative immunostaining of an atherosclerotic carotid lesion with (A) anti-CD68, (B) M1marker (anti-CD11c),
(C) M2 marker (anti-CD163 and anti-MR), and (D) anti–matrix metalloproteinase-2 and anti–matrix metalloproteinase-9. Upper images are from the asymp-
tomatic group, and lower images are from the symptomatic group. Scale bar, 100 mm.
K.Y. CHO ET AL.914medications are shown in Table 1. The 2 groups did not
differ significantly according to age, sex, individual risk
factors, medication, or coexistence of other vascular dis-
eases (angina pectoris, previous myocardial infarction,
and previous cerebrovascular disease). Overall, there
was no significant difference in metabolic risk factors (hy-
pertension, diabetes mellitus, or dyslipidemia). Basic bio-
chemical and hematologic parameters and inflammatory
parameters (white blood cell count and C-reactive pro-
tein) did not differ between the groups (Table 2).
The average carotid artery stenosis detected by ultra-
sound was not statistically different between the 2
groups; however, the frequency of unstable plaques (pla-
que with an irregular surface, ulceration, wall flap, or
with predominantly echolucent material) was consider-
ably higher in the symptomatic group (Chi-square test;
P 5 .033; Table 3).Representative immunostaining of plaques from both
asymptomatic and asymptomatic group are shown in
Figure 1. Macrophage-rich areas were identified by
CD681 immunostaining. This staining revealed that
plaques from the symptomatic group had a greater con-
centration of macrophages and especially M1 macro-
phages (CD11c1). In addition, enhanced staining of
MMP-2 and MMP-9 was observed in histologic sections
from symptomatic patients. Conversely, enhanced
expression of markers associated with alternative
M2 macrophage differentiation (CD163 and MR) was
observed in plaques from the asymptomatic group
(Fig 1).
Consistent with the immunostaining results, Western
blotting revealed increased protein expression of the M1
marker (CD68 and CD11c) in the symptomatic group pla-
ques and increased expression of the M2markers (CD 163
Figure 2. Differential expression of M1 and
M2 protein marker between symptomatic and
asymptomatic plaques. (A) Representative West-
ern blots for the CD 68 and M1 (CD 11c) and
M2 (CD 163 and MR) macrophage markers was
determined in carotid plaques from asymptomatic
and symptomatic patients. (B) Average protein
expression levels were normalized to b-actin and
are presented graphically for the markers. Gray
bar, asymptomatic group; black bar, symptom-
atic group. n 5 65 (34 for asymptomatic group
and 31 for symptomatic group). Data presented
as mean 6 standard deviation. *P , .05
(Mann–Whitney U test).
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(Fig 2).
Relative mRNA expression of the M1 markers CD68
(3.7-fold) and CD11c (3.3-fold) were significantly higher
in the plaques from symptomatic patients compared to
the asymptomatic patients. Monocyte chemoattractive
protein-1 (MCP-1; 3.4-fold), interleukin-6 (IL-6; 9.6-fold),
and MMP-9 (10.6-fold) expression was significantly
increased in the symptomatic plaques (Fig 3A). Real-
time PCR revealed that expression of the M1 markers
(CD68 [4.1-fold] and CD11c [5.7-fold]) were significantly
increased in the unstable plaques defined by ultrasound
analysis in symptomatic group (Fig 3B), while expression
of the M2 markers (CD163 [0.3-fold] and MR [0.1-fold])
was significantly lower in the unstable plaques defined
by ultrasound analysis in the asymptomatic group
(Fig 3C).Discussion
We characterized the phenotype of macrophages present
in symptomatic and asymptomatic plaques. Analysis of
plaque immunostaining and Western blotting revealed
a greater concentration of macrophages present in the pla-
ques isolated from the symptomatic group. In addition,
the majority of these macrophages were stained by CD11c,
which is indicative of a M1 macrophage population. In the
asymptomatic plaque, small numbers of macrophages are
observed, and they predominantly stained positive for M2
macrophage markers. Previous studies have reported
that increased macrophage volume and the presence of
inflammatory cytokines or chemokines in atherosclerotic ca-rotid plaqueswere associatedwith plaquevulnerability.16-18
During the preparation of this work, a study commented
on the relationship between plaque vulnerability and
macrophage polarity. However, these authors compared
the plaque to an adjacent nonatherosclerotic zone in the
carotid artery in identical patients, and found that both
M1 and M2 macrophages were more abundantly
expressed in the plaque area.3 We are the first authors to
compare the polarity of macrophages in plaques from
symptomatic or asymptomatic patients. Our data show
thatM1macrophage expression is exclusive to symptomatic
plaques while M2 macrophages are present in both symp-
tomatic and asymptomatic plaques.
Gene expression of proinflammatory cytokines and che-
mokines, such as IL-617 orMCP-1,19 is increased in the pla-
ques of the symptomatic group compared with the
asymptomatic group. These data are in agreement with
previous reports showing that vulnerable plaques contain
large numbers of macrophages and lymphocytes. This is
also consistent with our observation that expression of
proinflammatory M1 macrophages is elevated in the
symptomatic group plaques. The ratio of the increase in
IL-6 compared with that of IL-10 suggests that both M1
and M2 macrophages increase in the symptomatic group
compared with asymptomatic group, and that the M1
phenotype is much more predominant in the symptom-
atic group. Enhancement of MMP-2 and MMP-9 contrib-
utes to plaque rupture by inducing tissue fragility.20-23
MMP-2 and MMP-9 were found to be more greatly ex-
pressed by proinflammatory M1 macrophages in symp-
tomatic patients. These data suggest that a series of
events linked to M1macrophage infiltration are occurring
Figure 3. Differential expression of M1/M2 markers, inflammatory cytokines, and fibrinolytic enzymes between the symptomatic and asymptomatic groups or
between stable and unstable plaques in separate groups. (A) Inflammatory cytokines and fibrinolytic enzymes are increased in symptomatic plaques. Relative
mRNA expression of the M1/M2 markers, inflammatory cytokines, and fibrinolytic enzymes was assessed with real-time polymerase chain reaction. mRNA ex-
pression level of plaques from patients with stable plaque was designated as 1.0. Gray bar, asymptomatic group; black bar, symptomatic group. n 5 65 (34 for
asymptomatic group and 31 for symptomatic group). (B and C) M1 markers are increased in unstable plaques in symptomatic group, while M2 markers are in-
creased in stable plaques in asymptomatic group. Relative mRNA expression of the M1/M2 markers was assessed with real-time polymerase chain reaction.
mRNA expression level of stable plaques was designated as 1.0. Gray bar, stable plaques; black bar, unstable plaques. n 5 65 (32 for stable plaques and 33
for unstable plaques). Data presented as mean 6 standard deviation. *P , .05. **P , .01 (Mann–Whitney U test).
K.Y. CHO ET AL.916in the symptomatic group plaques that are influencing
plaque stability and predisposing them to collapse.
It is clear that diabetes mellitus,24,25 dyslipidemia,26,27
hypertension,28 and metabolic syndrome29 are associated
with the development and progression of atherosclerosis.
A number of large clinical trials with an endpoint of athero-
sclerotic disease show that rigorous risk management sup-
presses the progression of arteriosclerosis.30-33 However,
the association between plaque stability and clinical
measures is more complex. Several studies have shown an
association between carotid plaque stability and
differences in background or clinical parameters.34,35 In
contrast, our study and others have reported no significant
differences in background or clinical parameters between
symptomatic and asymptomatic patients.21,22,36 This lack
of consistent correlation between clinical measures and
plaque stability may be explained by the duration
a patient has had atherosclerotic disease and/or when
a medical treatment for the disease was initiated.
Specifically in our study, most patients in the symptomaticand asymptomatic groups had been routinely receiving
several antiatherosclerotic agents, and it is feasible that
clinical laboratory values were normalized in advance of
changes in plaque stability. This hypothesis is supported
by separate studies where MMP22 and cholesterol uptake
genes37 remained up-regulated in the arteriosclerotic pla-
ques of symptomatic patients even when their peripheral
bloodparameters hadbeennormalized.Additional longitu-
dinal studies will be required to clarify the relationship be-
tween plaque stability and traditional clinical diagnostic
measures. Although histologic analysis after clinical events
would be the best way to determine when macrophage po-
larity switches or is altered in plaques, this is not feasible for
human studies.
Another important finding of our study was that pla-
que morphology and not stenosis could be used as
a marker for symptomatic events. The contents of the pla-
que, including the polarity of macrophages, could be esti-
mated by ultrasound before surgery. Our data show that
the frequency of unstable plaques defined by ultrasound
MACROPHAGE PHENOTYPE INFLUENCES PLAQUE STABILITY 917was significantly higher in the symptomatic group, and
that expression of M1 macrophage markers was also sig-
nificantly elevated in plaques from the symptomatic
group. However, unstable plaques were observed in
both symptomatic and asymptomatic patient popula-
tions. In order to examine the association between macro-
phage polarity and plaque vulnerability, we further
investigated the gene expression profile of stable and un-
stable plaques within these 2 separate populations.
Consistent with our comparison of plaques from symp-
tomatic and asymptomatic patients, the unstable plaques
within the symptomatic population had increased expres-
sion of M1 markers and reduced expression of the M2
marker. This relationship became less apparent in the
asymptomatic patient plaques, because only the M2
marker was reduced. In this study, we investigated the re-
lationship between macrophage polarity and the vulnera-
bility of human atherosclerotic plaques and clinical
events. Macrophage polarity of atherosclerotic plaques
was associated with clinical incidence of ischemic stroke
and unstable plaques defined by ultrasound.
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